Serum FGF21 levels are elevated in patients with obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) [9] and could be considered as a biomarker of obesity-related metabolic diseases [23, 24]. This evidence concerns the gene FGF21 and obesity disorder.